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Abstract: Sarcoidosis-associated pulmonary hypertension (SAPH) is estimated to occur in at least 5% or more of sarcoidosis patients, and it
contributes to significant morbidity and mortality. Optimal therapy for SAPH is not well established. We performed a 24-week open-label trial
of tadalafil for SAPH at 2 academic medical centers. Subjects were required to have confirmed sarcoidosis plus a right heart catheterization
within 12 months of enrollment showing a mean pulmonary artery pressure ≥ 25 mmHg, a pulmonary artery wedge pressure ≤ 15 mmHg, and
a calculated pulmonary vascular resistance ≥ 3 Wood units. Subjects received 20 mg/day of tadalafil for the first 4 weeks and then 40 mg/day
for the subsequent 20 weeks. Sixteen patients were screened, 12 of whom met criteria for enrollment. At 24 weeks, there was no overall improve-
ment in 6-minute walk distance (6MWD). Five of the 12 subjects dropped out of the study early (2 for social reasons, 3 for medical reasons). There
was no significant change in short form 36, St. George’s respiratory questionnaire, or maximum Borg dyspnea scores over the 24 weeks. There
were no significant adverse events or laboratory abnormalities clearly related to tadalafil in the cohort. The study did not meet the primary end
point of change in 6MWD because of the small sample size. Tadalafil was generally safely administered in this cohort of SAPH patients. There
was a relatively high dropout rate but no major adverse events and no clinical worsening. Larger studies are needed to explore this question
further. (Trial registration: ClinicalTrials.gov identifier: NCT01324999)
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Sarcoidosis is a multiorgan system disease of unknown etiology, char-
acterized by noncaseating granulomatous tissue infiltration and in-
flammation. The most commonly affected organ system is the lung,
most often in the form of alveolitis and/or parenchymal fibrosis and
associated sequelae (such as bronchiectasis and cavity formation).
Sarcoidosis-associated pulmonary hypertension (SAPH) is seen in at
least 5% of patients with sarcoidosis1 and more often in patients with
advanced, end-stage disease. This higher frequency of SAPH is noted
particularly in patients who are being evaluated for or awaiting lung
transplantation, and increased mortality is noted in this population
as well.2-5 The optimal treatment approach to SAPH remains unclear.
Conventional corticosteroid and immunomodulator therapies (such
as methotrexate) utilized to treat sarcoidosis do not clearly improve
SAPH. Furthermore, there is a relative paucity of data with regard to
the utility of treating SAPH with pulmonary arterial hypertension
(PAH)-specific therapies.We report the results of a prospective, open-
label trial of tadalafil therapy in a defined cohort of SAPH patients.
The study was conducted at 2 academic medical centers in the United
States.
METHODS
This was an investigator-initiated study, approved by the institutional
review boards of the University of Cincinnati and the University of
North Carolina. Informed consent was obtained from each subject
before study entry.
Enrollment criteria
Subjects were recruited at the outpatient pulmonary clinics at the
University of Cincinnati and the University of North Carolina if they
met all of the following inclusion criteria: (1) confirmed sarcoidosis;
(2) right heart catheterization within 12 months of study enrollment,
with the following findings: mean pulmonary artery pressure (MPAP) ≥
25 mmHg, pulmonary artery wedge pressure ≤ 15 mmHg, and pul-
monary vascular resistance (PVR) ≥ 3 Wood units; (3) forced vital
capacity > 40% of predicted; (4) World Health Organization (WHO)
functional class (FC) 2 or 3; and (5) receiving stable sarcoidosis therapy
(e.g., corticosteroids) for at least 3 months before study entry. Subjects
were excluded from participation if they met any of the following crite-
ria: (1) use of any agent for treatment of PAH within 1 month of study
entry; (2) uncontrolled systemic hypertension; (3) pregnancy; (4) exer-
cise limitation from a cause thought other than a cardiopulmonary
cause (e.g., arthritis); (5) pulmonary hypertension (PH) thought not to
be related to sarcoidosis; (6) WHO FC 4; (7) significant left ventricular
dysfunction; (8) hepatic dysfunction thought not to be related to sar-
coidosis liver involvement; (9) presence of a comorbid illness thought
to affect survival during the course of the study.
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Drug administration
Subjects were screened for study eligibility within 30 days of enroll-
ment. Enrolled subjects received 20 mg daily of oral tadalafil starting
at enrollment (week 0) for 4 weeks. They then received 40 mg daily
of tadalafil until week 24 after enrollment. The drug was given in an
open-label fashion, with no control/placebo group. Reduction in the
dose of tadalafil back to 20 mg/day was allowed at the discretion of
study investigators if thought necessary.
Study end points
The primary efficacy end point was the change in the 6-minute walk
distance (6MWD) between week 0 and week 24. Secondary end points
included the change in the following parameters over the 24-week
study period: (1) WHO FC; (2) maximum modified Borg dyspnea
scale6 during the 6-minute walk test (6MWT); (3) St. George’s respi-
ratory questionnaire (SGRQ) score;7 (4) short form 36 (SF-36) score;
(5) serum pro-brain natriuretic peptide (BNP) level; and (6) oxygen
saturation nadir at rest and during 6MWT.
Data collection and safety monitoring
Subjects were interviewed and physical examination was performed
at study visits every 4 weeks until study completion (week 24). Study
subjects were asked about their level of dyspnea; presence of periph-
eral edema, wheezing, cough, or chest pain; and symptoms of liver
disease and right heart failure (e.g., syncope, near-syncope, abdomi-
nal distension). At each visit, the subjects underwent the following:
physical examination, including vital signs and pulse oximetry, and
a formal examination for the degree of peripheral edema; 6MWT,
where 6MWD with maximum Borg scale assessment, heart rate, ox-
imetry, and blood pressure were recorded; WHO FC determination;
serum BNP testing; and a pregnancy test for all female subjects with
childbearing potential. Spirometry, diffusing capacity, complete blood
counts, comprehensive metabolic panel, SGRQ scores, and SF-36
scores were measured at weeks 0, 8, 16, and 24. An assessment of
compliance with the study drug and of possible study drug toxicity
was made at the week 4 study visit and all subsequent visits. Subjects
Table 1. Baseline demographics and clinical characteristics (intent
to treat population; n = 12 unless otherwise noted)
Baseline characteristic Value
Age, years 54.5 ± 9.48
Sex, no. (%)
Male 4 (33)
Female 8 (67)
Race, no. (%)
Black 9 (75)
White 3 (25)
Sarcoidosis therapy, no. (%)
Corticosteroid 8 (67)
Methotrexate 5 (41.6)
Hydroxycholoroquine 1 (8.3)
None 3 (25)
Prednisone (or equivalents)
daily dose, mg 20.9 ± 12.7
Chest X-ray stage (n = 12)
0 1
1 0
2 1
3 6
4 4
Spirometry, percent predicted
FVC 65.9 ± 13.4
FEV1 58.0 ± 14.7
DLCO (n = 8) 60.3 ± 25.0
Severe airflow obstruction
(FEV1 < 50% predicted), no. (%)a 2 (16.7)
Isolated DLCO reduction, no. (%) 1 (8.3)
Principally restrictive disease suggested
by spirometry, no. (%) 4 (33)
Quality of life metrics
SF-36 global score 38.2 ± 5.1
SGRQ total score 62.5 ± 14.2
Hemodynamic data
Right atrial pressure, mmHg 6.2 ± 4.0
MPAP, mmHg 34.8 ± 7.1
PVR, Wood units (thermodilution) 6.2 ± 3.6
PAWP, mmHg 10.3 ± 3.6
Cardiac index, L/min/m2
(thermodilution) 2.4 ± 0.6
Oxygen and functional assessments
Requires supplemental oxygen
at rest, no. (%) 5 (41.6)
6-minute walk distance, m 360.0 ± 163.3
Maximum Borg score during 6MWT 5.0 ± 2.3
WHO functional class, no. (%)
2 7 (58.3)
3 5 (41.6)
Serum pro-BNP, pg/mL (n = 8) 77.6 ± 85.2
Note: Except where otherwise indicated, data are means ± SD.
6MWT: 6-minute walk test; BNP: brain natriuretic peptide; DLCO:
single-breath diffusing capacity for carbon monoxide; FEV1: forced
expiratory volume in 1 second; FVC: forced vital capacity; MPAP:
mean pulmonary artery pressure; PAWP: pulmonary artery wedge
pressure; PVR: pulmonary vascular resistance; SF-36: short form 36;
SGRQ: St. George’s respiratory questionnaire; WHO: World Health
Organization.
a Without proportionate decrease in FVC.
Table 1 (continued)
Baseline characteristic Value
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were allowed to receive diuretics to control peripheral edema as well
as treatment of any other complications or acute illnesses that oc-
curred during the course of the study.
Statistical analysis
The study design was open label, proof of concept. Baseline demo-
graphics were collected at the baseline or screening visit. Spirometry
and single-breath diffusing capacity for carbon monoxide (DLCO) pa-
rameters were documented as percent predicted of normal. SF-36
and SGRQ data were scored using algorithms and calculators pub-
lished and provided by Hays8 and the SGRQ score calculator.9
All study outcome variables were compared with baseline values
at weeks 8, 16, and 24. Student t tests were utilized to determine sig-
nificance of the changes observed between baseline and week 24 data.
When data were missing because of patient dropout or a missed study
visit, the last observation carried forward was used for interim and
final analyses.
RESULTS
Twelve subjects were enrolled in this study over a period of 29 months.
Table 1 displays the demographics and baseline characteristics of the
study cohort. The patients were predominantly African American
women. Most had mild to moderate PH (MPAP = 34.8 ± 7.1 mmHg),
which is consistent with previous reports of SAPH.10 The majority
of the subjects (7/12 [58%]) had WHO FC 2 status at the time of en-
rollment.
With regard to the disposition of the subjects (Fig. 1), 58% (7/12)
of subjects completed this 24-week trial. Of the 5 subjects who dis-
continued this study, 3 (60%) discontinued for adverse effects (head-
ache [n = 2] or joint pain [n = 1]), while 2 (40%) discontinued for
social reasons (lack of continued interest or inability to attend further
study visits). In terms of timing of study discontinuation, 3 (60%) of
those who discontinued did so within 8 weeks of enrollment, and the
remaining 2 (40%) discontinued after week 8.
Subjects who discontinued tadalafil and dropped out of the study
for any reason could not be predicted by development of edema,
6MWD, Borg score, baseline supplemental oxygen requirement,
WHO FC, SF-36 score, or SGRQ score (data not shown). Of those
who received at least 1 dose of study drug, none developed hepatic
or renal impairment during this trial, on the basis of interval assess-
ments of liver transaminases, bilirubin, and serum creatinine. Further-
more, no subjects developed significantly increased peripheral edema
during the course of the study, on the basis of investigator physical
examination assessment at each study visit. One subject changed the
dose of immunomodulatory medications during the trial (reduction
of prednisone from 40 to 30 mg/day at week 12). In addition, there
was one subject who reduced the dose of tadalafil back to 20 mg daily
after week 4 because of joint pain (resolved after dose decrease, and
the patient remained in the trial for the full duration).
In addition to the aforementioned joint pain and headache, 2 other
patients experienced adverse effects of herpes zoster and influenza com-
plicated by pneumonia. Both were thought to be unrelated to the study
drug and were resolved with appropriate therapy. All of the adverse
events noted in the study population are reported in Table 2.
The study’s primary end point—a significant change in 6MWD
between week 0 and week 24—was not met in the 6 of the 7 study
completers who performed the 6MWT through week 24 (Fig. 2;
Table 3). The following secondary end points also did not signifi-
cantly change after 24 weeks of tadalafil therapy: maximum modi-
fied Borg dyspnea scale during the 6MWT, SF-36 and SGRQ scores,
and serum BNP level (Table 3). One patient did change their WHO
FC from baseline to week 24, improving from FC 2 to class 1. Ox-
Figure 1. Disposition of study subjects with duration of treatment and reasons for study drop-out. 6MWT: 6-minute walk test.
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ygen requirement at rest and nadir during 6MWT did not change
significantly during the course of the trial in this cohort.
DISCUSSION
This proof-of-concept trial did not show a significant difference in
the primary efficacy end point of 6MWD at 24 weeks in SAPH
patients treated with tadalafil. This was largely due to small sample
size and compounded by patient dropouts. This is consistent with
what was observed by Judson et al.11 in a similarly sized open-label
trial of ambrisentan for SAPH that enrolled slightly more patients
(n = 21). Our sample size was further reduced by study dropouts,
making it even less likely to detect a trend toward statistical signifi-
cance with any of our measures. Interestingly, one patient who com-
pleted the study did demonstrate a 46-m improvement in 6MWD
(Fig. 1), far above the minimal important difference of 33 m estab-
lished for PAH patients.12 This particular patient had mild PH
(MPAP = 25 mmHg) and severe airway obstruction (forced expira-
tory volume in 1 second = 46% predicted).
A significant number of patients dropped out of the study early
as a result of known adverse effects of tadalafil (headache and joint
pain). Three of the patients who remained in the trial for the full
24 weeks actually experienced a decline in their 6MWD. The rea-
son for this is unclear, but one possible explanation is worsening of
ventilation/perfusion (V/Q) mismatch in patients with parenchy-
mal lung disease due to administration of a pulmonary vasodilator
agent (tadalafil). All three of these patients had stage 3 radiographic
disease. However, none of the patients in the trial clearly demon-
strated worsening of oxygen saturation while receiving tadalafil ther-
apy, which would be an expected consequence of increased V/Q mis-
match.
We also sought to evaluate safety and tolerability in this cohort
of SAPH patients exposed to tadalafil. As stated above, the num-
ber of adverse events was small. Joint pain/arthralgia and head-
ache are known adverse effects of tadalafil. The two other patients
who developed infectious complications (herpes zoster and influenza
with pneumonia) were both on significant immunosuppressant reg-
imens consisting of prednisone and methotrexate as therapy directed
at sarcoidosis.
With regard to SF-36 and SGRQ scores, there was no signifi-
cant improvement over the 24-week trial. Similarly, there was no
improvement noted in WHO FC, as assessed by the investigators.
Thus, there seems to be general agreement between investigator
and patient self-assessment of functional capacity.
There was no significant difference noted in pro-BNP levels from
baseline to week 24. However, the baseline levels were within normal
range before treatment, suggesting that most of the patients did not
have significant right ventricular strain due to PH at the outset of
the study. Indeed, the average baseline cardiac index was within nor-
mal range. The right atrial pressures were not elevated, indicating that
the patients were relatively euvolemic (Table 1) without significant right
heart strain.
Aside from small sample size, the multifactorial nature of SAPH
has made it very difficult to identify any signal of efficacy from PAH
therapies in general. Isolated, intrinsic pulmonary arteriopathy (pos-
sibly in the form of granulomatous vascular disease) may be seen in
a small number of SAPH patients. However, the majority of SAPH
patients have left heart dysfunction (WHO group 2 PH) and/or re-
strictive lung disease related to parenchymal fibrosis (WHO group 3
PH). Most trials of PAH therapy for SAPH have had small sample
sizes and were not placebo controlled. Furthermore, many have been
retrospective and/or observational studies.13-15 Overall, the body of
literature looking at PAH therapies to treat SAPH has not shown a
benefit in traditional PAH trial end points. One exception to this is
Table 2. Adverse events experienced in patients who received at least 1 dose of study drug, with reported severity, outcome,
and relationship to study drug
Adverse event No. (%) Severity Relationship to study drug Outcome
Headache 2 (17) Adverse event Probably related Resolved with cessation of study drug
(patient dropped out)
Joint pain 1 (8) Adverse event Probably related Resolved with cessation of study drug
(patient dropped out)
Herpes zoster 1 (8) Adverse event Unrelated Resolved with treatment
Influenza and pneumonia 1 (8) Adverse event Unrelated Resolved with treatment
Figure 2. Six-minute walk distance of the 6 patients who completed
the 6-minute walk test from baseline through week 24, with each dis-
tance shown at every 4 weeks.
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a recent study by Baughman et al.16 looking at the efficacy of bosen-
tan for SAPH in a 16-week, double-blind, placebo-controlled trial.
In that study, no difference was observed in 6MWD, but significant
improvements were seen in MPAP and PVR at week 16. Our study
did not look at hemodynamics at week 24, but it is possible that they
may have improved. Milman et al.17 found that treating SAPH with
sildenafil was associated with improvement in hemodynamics but
not 6MWD. Changes in pulmonary hemodynamics may not result
in functional or 6MWT improvement within the 24 weeks of this
study and thus may require a more prolonged course of treatment to
improve 6MWD and functional capacity.13
There are limitations to this study, the most significant being the
unblinded, open-label study design with no placebo control group.
As stated above, the small sample size also limits the ability to detect
significant differences in all of the study end points. In addition to
these design and sample size issues, it is possible that the exclusion
criteria for forced vital capacity (≥40% predicted) was too liberal.
This could have allowed for patients who were less likely to have in-
trinsic pulmonary arteriopathy and more likely to have SAPH driven
largely by parenchymal fibrosis and destruction/distortion. One could
argue that a PAH-specific therapy is not as likely to improve outcomes
in this context. Another possibility is that the dosing schedule em-
ployed in the study was not optimal for this population. In the Pul-
monary Arterial Hypertension and Response to Tadalafil (PHIRST)
trial of tadalafil for PAH, it was noted that 20 mg daily of tadalafil
improved 6MWD almost as much as 40 mg daily and that the in-
crease was significant compared with placebo.18 Given the aforemen-
tioned hypothesis that some SAPH may actually develop worsening
V/Q mismatch with PAH therapy, it is plausible that a lower dose of
tadalafil for the duration of this trial may have led to beneficial func-
tional and hemodynamic outcomes while mitigating some of the po-
tential V/Qmismatch.
In summary, though the primary and secondary efficacy end
points were not met, we were able to glean some preliminary safety
and tolerability data with respect to the use of tadalafil in SAPH.
Seven out of 12 patients were able to continue tadalafil therapy and
complete the study. Those who withdrew because of medical rea-
sons experienced known side effects of tadalafil. There was no clear
clinical worsening on the basis of the end points assessed over the
24-week duration of the study. None of the patients required addi-
tional therapy or hospitalization. There was no indication of harm
in terms of hepatic, renal, or other organ system dysfunction. The
exact role tadalafil may play in this population remains unclear.
A more rigorous, larger, and/or longer controlled trial with stricter
inclusion/exclusion criteria might identify a cohort of SAPH pa-
tients who would benefit from tadalafil therapy.
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